Part 1: Review, Review Author and Study Information
Review title:
Review author:
Date of completion of this form:	Year / Month / Day
Study ID:
Author(s):
Title of Report:
Year of publication:
Source:
Language of publication:	English / Dutch / French / German / Other (specify)
Type of report:	Full paper / Abstract / Unpublished
Number of centres:	Single centre / Multicentre (if multicentre, number of centres)
Date trial was conducted:
Country where study performed:
Funders of the trial:
Study found in:	Electronic databases / Trials registries / Manual searches of conference proceedings
Unpublished data:	Yes / No
Part 2: Eligibility of Study for Review
Study Type
A randomized controlled trial:	Yes / No / Unclear
Type of randomization:
Study Participants
(critically ill) adults:	Yes / No / Unclear
Invasively ventilated:	Yes / No / Unclear
Study Intervention
Comparison between silver‐coated ETTs or a combination of silver with any antimicrobial‐coated ETTs with standard non‐coated ETTs or with other antimicrobial‐coated ETTs such as chlorhexidine‐coated ETTs.	Yes / No / Unclear
Outcome
Primary Outcome:
The study reports the following outcomes:
Number of participants with VAP:	Yes / No / Unclear
Hospital mortality:	Yes / No / Unclear
Secondary Outcome:
Device‐related adverse events:	Yes / No / Unclear
Cost‐effectiveness of the silver‐coated ETTs (author's definitions):	Yes / No / Unclear
Length of hospital and ICU stay:	Yes / No / Unclear
Time to VAP onset:	Yes / No / Unclear
Review Exclusion Criteria
The study includes:
Children under 16 years:	Yes / No / Unclear
Participants who are re‐intubated:	Yes / No / Unclear
Participants requiring planned short‐term ventilation (< 24 hours):	Yes / No / Unclear
Part 3: Description of the Study
Characteristics of the Participants
Study inclusion criteria:
Study exclusion criteria:
	Intervention group			Control group	TOTAL
Number of participants:
Mean age (SD) (range):
Sex (F/M):
Participants excluded from the study before randomization:	Number:			Number:	Number:
	Reason:			Reason:
Participants excluded from the study after randomization:	Number:			Number:	Number:
	Reason:			Reason:
Withdrawals:	Number:			Number:	Number:
	Reason:			Reason:
Length of follow‐up:	Number:			Number:	Number:
Unit of randomization:	Participant / endotracheal tube / other
Types of Interventions
The intervention group:
The control group:
Setting of intervention:	Emergency department / Operating theatre / ICU / Other (specify)
	Intervention group	Control group
Antibiotics given:	Yes / No / Unclear	Yes / No / Unclear
If yes, mention the duration of antibiotics given in hours:
Continuous Outcomes
	Intervention group			Control group				95% CI or additional information
Outcomes	n	Mean (SD)	Median (IQR)	n	Mean (SD)	Median (IQR)	P value
Primary Outcome:
Participants with VAP:
Hospital mortality:
Other (specify):
Secondary Outcome:
Device‐related adverse events:
Length of hospital and ICU stay:
Cost‐effectiveness of the silver‐coated ETTs:
Time to VAP onset:
Other (specify):
Dichotomous Outcomes
	Intervention group		Control group
Outcomes	n		n	P value	Risk difference (RD)	Number needed to treat for an additional beneficial outcome (NNTB)	Risk Ratio	Additional information
Primary Outcome:
Participants with VAP:
Hospital mortality:
Other (specify):
Secondary Outcome:
Device‐related adverse events:
Length of hospital and ICU stay:
Cost‐effectiveness of the silver‐coated ETTs:
Time to VAP onset:
Other (specify):
Scale/Measure (Definition/Description of How It Was Measured)
Hospital mortality:
Device‐related adverse events:
Cost‐effectiveness of the silver‐coated ETTs:
Other (specify):
Date:___/___/___	Review author‘s signature